Navigation Links
RBC Life Sciences Reports Second Quarter 2011 Results

IRVING, Texas, Aug. 11, 2011 /PRNewswire/ -- (RBC Life Sciences: OTCQB: RBCL) - RBC Life Sciences, Inc., a provider of proprietary nutritional supplements, wound care and pain management products, today reported consolidated net sales of $7.5 million for the quarter ended June 30, 2011, compared to net sales of $7.8 million for the same period during 2010.  The Company also reported net earnings of $17,000, or $0.00 per share, compared to net earnings of $172,000, or $0.01 per share, for the same quarter last year.  Net sales were $14.0 million and $14.8 million for the six months ended June 30, 2011 and 2010, respectively, while net earnings were $160,000 and $383,000 for the six months ended June 30, 2011 and 2010, respectively.

"Due to a variety of logistical factors and weakness in some international markets, net sales in our largest revenue channel declined during the first six months of 2011 resulting in an overall decline in consolidated net sales and net earnings," said RBC Life Sciences President and CEO, Clinton H. Howard. "However, we continue to see growth in Associate network sales, which increased 57% during the first six months of 2011.  Sales growth in this channel accelerated during the second quarter following the introduction in May of our exciting new product, Stem-Kine™."

Stem-Kine is a dietary supplement that has been shown in published human clinical studies to nutritionally enable bone marrow and other stem-cell-producing tissues to increase their production of stem cells, which form the natural repair and renewal system of the body.  The Company distributes Stem-Kine under an exclusive license agreement that covers the U.S. and 41 other countries.

About RBC Life SciencesThrough wholly owned subsidiaries, RBC Life Sciences develops, manufactures and markets high-quality nutritional supplements and personal care products under its RBC Life brand to a growing population of consumers seeking wellness and a healthy lifestyle. Through its wholly owned subsidiary, MPM Medical, the Company also develops and markets to health care professionals in the United States proprietary prescription and nonprescription products for advanced wound care and pain management. All products are tested for quality assurance in-house, and by outside independent laboratories, to comply with regulations in the U.S. and in more than thirty countries in which the products are distributed. For more information, visit the company's website at

The statements above, other than statements of historical fact, may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to, changes in plans by the Company's management, delays or problems in production, changes in the regulatory process, changes in market trends, and a number of other factors and risks described from time to time in the Company's filings with the Securities and Exchange Commission.RBC Life Sciences, Inc.Summary Results of Operations(in thousands, except per share data)(unaudited)Quarters Ended June 30,20112010Net sales



7,838Gross profit

3,9853,656Operating profit

57357Earnings before income taxes

22318Provision for income taxes

5146Net earnings

17172Earnings per share - basic



0.01Earnings per share - diluted


0.000.01Weighted average shares outstanding - basic

22,22921,922Weighted average shares outstanding - diluted

22,54822,387Six Months Ended June 30,20112010Net sales

14,03214,820Gross profit

7,3017,045Operating profit

319757Earnings before income taxes

247679Provision for income taxes

87296Net earnings

160383Earnings per share - basic



0.02Earnings per share - diluted



0.02Weighted average shares outstanding - basic

22,22921,922Weighted average shares outstanding - diluted

22,54722,322RBC Life Sciences, Inc.Condensed Consolidated Balance Sheets(in thousands)(unaudited)June 30,December 31,20112010AssetsCash and cash equivalents




5,5485,343Other current assets

2,1561,696Total current assets

13,31811,259Other assets

6,9327,085Total assets



18,344Liabilities and shareholders' equityAccounts payable and accrued liabilities



3,087Deferred revenue

3,5732,490Other current liabilities

175168Total current liabilities

7,5595,745Other liabilities

2,6362,723Shareholders' equity

10,0559,876Total liabilities and shareholders' equity




SOURCE RBC Life Sciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
2. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
3. Ardea Biosciences to Present at Wedbush Securities Life Sciences Conference
4. BioMarin to Present at the Wedbush Life Sciences Conference
5. Ikaria® to Present at 2011 Wedbush Life Sciences Management Access Conference
6. Cardica to Present at the Wedbush Life Sciences Management Access Conference
7. Caliper Life Sciences Reports Second Quarter 2011 Results
8. BGI and GT Life Sciences, Inc. Report Genome Sequence of CHO-K1 and Provide New Insights into Optimization of Biopharmaceutical Protein Production
9. Caliper Life Sciences to Present at the Leerink Swann Life Science Tools & Diagnostics Roundtable
10. Caliper Life Sciences Second Quarter Results Conference Call Notice
11. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2011 Financial Results
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  Mindray Medical ... MR ), a leading developer, ... worldwide, today announced that it will ... of shareholders at the Company,s Hong Kong office ... Prince Edward West Road, Mongkok KL, Hong ...
(Date:11/25/2015)... - Will Also Offer Point ... (CME) --> - Will Also Offer ... (CME) --> - Will ... Education (CME) Elsevier , a world-leading ... feature latest diagnostic imaging textbooks and decision support tools, as well ...
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... the perfect dish and pleasing the palates of attendees is of the utmost ... dish to a seasonal get-together, give these recipes a try this holiday season. ...
(Date:11/25/2015)... , ... November 26, 2015 , ... ... Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public ... in Nairobi (UNON) for the opening of the 5th African Network for Drugs ...
(Date:11/25/2015)... Cleveland, OH (PRWEB) , ... November 25, 2015 , ... ... dental implants in Cleveland, OH , are invited to attend Dr. Mark Iacobelli’s Advanced ... 5th this year in Cleveland, OH. , As the co-founders of Advanced Implant ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of ... patients are aware of the benefits of Botox® in the treatment of moderate facial ... discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a passenger ... thought there had to be a convenient and comfortable way to protect them from ... disabled individuals to safely travel during cold or inclement weather. In doing so, it ...
Breaking Medicine News(10 mins):